ATL (ADVANCED TECHNOLOGIES LABORATORY) R&D sarl.

ATL was founded by Dr. Moncef BenKhalifa in Paris In 1998. ATL provides consultancy, technology transfer and training to IVF, andrology, genetics, and molecular biology laboratories worldwide. ATL geographically extended its services to Europe as well as the Middle East and North Africa. In 2002, ATL established and validated a new R&D facility for “Genomic Research”.

In 2003, ATL and a Turkish biotechnology company, Medimiks, decided to merge their companies and hence transferred shares to each other. (Today, Medimiks holds 3.6% of ATL’s shares and ATL holds 9% of Medimiks’ shares). These companies began working together in the field of biotechnology and provide advanced technology and complete product mix to IVF and genetics laboratories. The reputation of their services is based upon the quality of their know-how; from production through to sales and after sales technical support.

In 2007, ATL transferred its know-how in microarray technology to Medimiks and participated in Medimiks’ EUREKA project titled “Development and commercialization of microarray for molecular karyotype by CGH Array”. This R&D project was completed in 2009.

Until 2009, ATL’s R&D activities were about “Genomics”, which is mainly for understanding the contribution of genomic disorders in reproductive pathology. Starting in 2010, ATL changed its focus to “Transcriptomics”, which helps to understand the genome expression profile on oocyte and sperm competency in severe infertility cases which is around 17% of the all infertile cases. The developments in this new field will change the rules in management of reproductive diseases. Revolutionary changes in the pharmaceutical industry and assisted reproductive technologies are expected.